Perrigo Co Plc Stock Price, News & Analysis

Perrigo Company plc (NYSE: PRGO) has announced that it will release its financial results for the fourth quarter and fiscal year 2022 on February 27, 2023, after U.S. markets close. Following this, a Virtual Investor Day is scheduled for February 28, 2023, at 8:00 AM EST. Investors and interested parties are invited to register for the event online. This announcement is part of Perrigo's ongoing commitment to transparency and investor engagement. The company specializes in consumer self-care products and OTC health solutions, aiming to empower consumers in managing their health.

Perrigo Company plc (NYSE: PRGO) announced a Virtual Investor Day on February 28, 2023, coinciding with its quarterly earnings. During this event, management will outline its 2023-2025 strategic plans aimed at optimizing performance and enhancing market share growth. Key initiatives include a global supply chain program to improve gross margins, a focus on cash generation, and a capital allocation strategy prioritizing dividends and debt reduction. The event starts at 8:00 a.m. EST and will feature executive presentations.

ACO, a leading Swedish skincare brand, is launching its products in the U.S. this holiday season. Known for its clean and effective beauty solutions, ACO has been a staple in Scandinavian skincare since 1939. With a commitment to vegan, cruelty-free products, ACO offers a diverse range, including the new Sensitive Balance and Pure Glow lines. This holiday, ACO introduces seasonal skincare bundles at a 10% discount, ideal for gifting. The brand's reputation for quality and innovation, adhering to strict EU standards, positions it for success in the competitive U.S. market.

Perrigo reported third quarter net sales of $1.1 billion, a 5.5% increase year-over-year (12.3% excluding currency effects). Year-to-date net sales rose 8.7%, with organic sales up 7.7% in Q3. Gross margin was 33.0% (adjusted: 36.5%), with adjusted operating income of $133 million, a 19.2% increase. Reported EPS loss was ($0.39), improved from ($0.40) YOY. The company maintains its fiscal 2022 organic sales growth forecast of 9.0%-10.0% but revised adjusted EPS guidance to $2.00-$2.10.

Perrigo Company plc (NYSE: PRGO) announced a quarterly dividend of $0.26 per share, payable on December 20, 2022, to shareholders of record on December 2, 2022. This decision reflects the company's ongoing commitment to shareholder value as a leading provider of Consumer Self-Care Products. The press release also discusses forward-looking statements related to their investments in infant formula capacity and highlights potential risks including the impact of COVID-19, economic conditions, and ongoing litigation.

Perrigo Company plc (NYSE: PRGO) has announced a $170 million acquisition of Nestlé's Gateway infant formula plant in Eau Claire, Wisconsin and U.S. and Canadian rights to the Good Start^® brand. This investment aims to increase production capacity by 7 million pounds, enhancing consumer access to affordable infant formula. The initiative is part of Perrigo's Supply Chain Reinvention program, expected to boost net sales and earnings per share. The transaction is funded without additional debt and aligns with Perrigo's commitment to improving supply and quality in the infant formula market.

Perrigo Company plc (NYSE: PRGO) announced that the FDA has postponed the joint advisory meeting originally set for November 18, 2022, concerning the review of Opill®, a daily oral contraceptive for OTC use. The FDA needs additional information, extending the Prescription Drug User Fee Act (PDUFA) date by 90 days. Opill® aims to be the first OTC daily birth control pill accessible without a prescription in the U.S. Perrigo continues to collaborate with the FDA for a thorough review.

Perrigo Company plc (NYSE: PRGO) will release its third quarter 2022 financial results on November 8, 2022, at 8:30 A.M. (EST). A conference call will follow, available via webcast on the investor relations section of the Perrigo website or by phone. The replay of the call will be accessible from November 8 at 12:00 P.M. until November 15. Perrigo is a leading provider of Consumer Self-Care Products that empower consumers to manage their health independently.

Perrigo Company plc (NYSE: PRGO) announced that the FDA will hold a joint meeting on November 18, 2022, to review its application for Opill^®, a daily oral contraceptive, for over-the-counter (OTC) use. This could mark Opill^® as the first daily birth control pill available OTC in the U.S. The application was filed by Perrigo's affiliate, HRA Pharma. However, the outcome of the FDA's review remains uncertain, and there are risks associated with regulatory approval.